Alan H. Auerbach Sells 33,841 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach sold 33,841 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total transaction of $106,599.15. Following the sale, the chief executive officer now owns 7,029,674 shares in the company, valued at approximately $22,143,473.10. This trade represents a 0.48 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Puma Biotechnology Price Performance

Shares of NASDAQ:PBYI opened at $2.95 on Monday. The business has a fifty day moving average price of $2.99 and a 200-day moving average price of $2.97. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. The company has a market capitalization of $144.81 million, a PE ratio of 6.15 and a beta of 1.10. Puma Biotechnology, Inc. has a 1-year low of $2.22 and a 1-year high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.31 by $0.10. The company had revenue of $80.50 million for the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. During the same period in the prior year, the firm posted $0.12 EPS. As a group, equities analysts expect that Puma Biotechnology, Inc. will post 0.31 EPS for the current fiscal year.

Institutional Investors Weigh In On Puma Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in PBYI. SG Americas Securities LLC bought a new position in Puma Biotechnology in the 3rd quarter valued at approximately $34,000. Franklin Resources Inc. purchased a new position in shares of Puma Biotechnology in the third quarter worth $41,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Puma Biotechnology during the third quarter valued at $44,000. Patriot Financial Group Insurance Agency LLC boosted its position in shares of Puma Biotechnology by 72.7% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 8,000 shares during the last quarter. Finally, Royce & Associates LP boosted its position in shares of Puma Biotechnology by 71.8% during the third quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 8,427 shares during the last quarter. Institutional investors own 61.29% of the company’s stock.

Wall Street Analysts Forecast Growth

PBYI has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Puma Biotechnology in a research report on Monday, December 23rd. StockNews.com cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.